Skip to Main Content

Paper Details

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Cancer Discov
226
2019
ATP, BGJ398, Debio, Debio 1347, FGFR, FGFR2, FGFR2 fusion-positive ICC, FGFR2 gene fusions, FGFR2 kinase domain, FGFR2 mutations, ICC, ICC models, Patients, TAS-120, circulating tumor DNA, ctDNA, fibroblast growth factor receptor, fusion, intrahepatic cholangiocarcinoma, patient, patient-derived ICC cells, patients, polyclonal cell pools, tumor
Author NameAffiliation
Jochen K LennerzMassachusetts General Hospital, Harvard Medical School
Phuong VuCancer Center, Massachusetts General Hospital, Harvard Medical School
Krushna C PatraCancer Center, Massachusetts General Hospital, Harvard Medical School
Anthony J IafrateMassachusetts General Hospital, Harvard Medical School
William C HahnDana-Farber Cancer Institute, Harvard Medical School
William C HahnBroad Institute of Harvard and MIT
William C HahnDana-Farber Cancer Institute, Harvard Medical School
William C HahnBroad Institute of Harvard and MIT
Cyril H BenesCancer Center, Massachusetts General Hospital, Harvard Medical School
Gad GetzCancer Center, Massachusetts General Hospital, Harvard Medical School
Gad GetzBroad Institute of Harvard and MIT
Gad GetzCancer Center, Massachusetts General Hospital, Harvard Medical School
Gad GetzBroad Institute of Harvard and MIT
Nabeel BardeesyCancer Center, Massachusetts General Hospital, Harvard Medical School
Nabeel BardeesyBroad Institute of Harvard and MIT
  • 1 - 15

Datasets

Release 1.2